Adagene Inc. revenue

Adagene Inc.'s revenue was $7.7m in fiscal 2025, up 7332.8% on the year before. Since fiscal 2018 ($1.5m) it has grown at a compound 26.1% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Adagene Inc.: revenue history, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	2	0	1	10	9	18	0	8
Growth on the year before	—	−68.2%	+46.0%	+>999%	−8.7%	+94.9%	−99.4%	+>999%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Adagene Inc.	$7.7m	7332.8%	—
Roivant Sciences Ltd.	$7.5m	-67.6%	-46.4%
Evaxion A/s	$7.5m	125.1%	—
Coya Therapeutics, Inc.	$8.0m	1793.8%	—
Aclaris Therapeutics, Inc.	$8.2m	-51.0%	-35.9%
Tscan Therapeutics, Inc.	$7.1m	2.2%	-24.3%

Compare with peers

Head to head: ADAG vs ROIV ADAG vs EVAX ADAG vs COYA ACRS vs ADAG

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Adagene Inc.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Adagene Inc.